Insulet upgraded by Wolfe Research with a new price target
$PODD
Medical/Dental Instruments
Health Care
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $365.00 | Buy | Truist |
| 5/30/2025 | $380.00 | Buy | Goldman |
| 5/13/2025 | $350.00 | Peer Perform → Outperform | Wolfe Research |
| 4/29/2025 | Outperform → Peer Perform | Wolfe Research | |
| 3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diab
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration represents a major milestone in our commitment to providing innovative solutions for diabetes manage
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions throug
Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00
Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00